New Two-Drug attack tested to shrink tumors before cancer surgery
NCT ID NCT07465276
Summary
This study is testing whether giving two drugs—ficerafusp alfa (an experimental drug) and pembrolizumab (an approved immunotherapy)—before surgery can help shrink tumors and improve outcomes for people with high-risk, operable head and neck cancer. The goal is to see if this pre-surgery treatment is safe and effective at reducing the amount of cancer found in the tissue removed during surgery. About 32 participants with a specific type of cancer that tests positive for a marker called PD-L1 will be enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.